Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics


Madrigal Pharmaceuticals, Inc. (MDGL): $65.24

-2.12 (-3.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDGL Stock Price Chart Interactive Chart >

Price chart for MDGL

MDGL Price/Volume Stats

Current price $65.24 52-week high $105.93
Prev. close $67.36 52-week low $52.33
Day low $64.18 Volume 339,200
Day high $70.46 Avg. volume 230,269
50-day MA $69.16 Dividend yield N/A
200-day MA $74.09 Market Cap 1.12B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.


MDGL Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream


Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Haemonetics (HAE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL – Research Report) and Haemonetics (HAE – Research Report). Madrigal Pharmaceuticals (MDGL) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $182.00. The company's shares closed last Monday at $64.62. According to TipRanks.

Christine Brown on TipRanks | November 7, 2022

Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH cirrhosisScreening data from the Phase 3 MAESTRO-NASH biopsy study provide new insights on noninvasive strategies for patient identification Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Nov. 03, 2022 (GLOBE NEWSWIR

Yahoo | November 3, 2022

B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)

E ratio of -4.90.

Brian Anderson on TipRanks | November 2, 2022

A Chronic Disease Still Waiting for a Drug

As biotech companies take new shots at fatty liver disease, investor skepticism and potential payoffs are high.

Yahoo | September 20, 2022

Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon

NASH is a common disease, but there are no approved treatments for it. These two drug companies have promising candidates in clinical trials.

Yahoo | September 15, 2022

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo 2.31%
3-mo 0.59%
6-mo -11.59%
1-year -11.20%
3-year -44.95%
5-year -20.02%
YTD -23.01%
2021 -23.77%
2020 22.02%
2019 -19.17%
2018 22.80%
2017 516.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.653 seconds.